Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
RBC Lifts Price Target on Axsome Therapeutics to $131 From $130, Keeps Outperform Rating
The Five-year Returns Have Been Enviable for Axsome Therapeutics (NASDAQ:AXSM) Shareholders Despite Underlying Losses Increasing
Express News | Axsome Therapeutics: Fifth Amendment to Increase Tranche 3 Commitment From $75 to $80 Mln
Express News | Axsome Therapeutics: On September 30 Entered Into Fifth Amendment to Its Loan & Security Agreement Dated Sept 25, 2020